AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Phase 3positiveEpcoritamabR-CHOPPositive
AI Analysis
Summary
AbbVie and Genmab announced that epcoritamab combined with R-CHOP demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to R-CHOP alone in the Phase 3 EPCORE DLBCL-2 trial for newly diagnosed diffuse large B-cell lymphoma patients.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Epcoritamab in combination with R-CHOP demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus R-CHOP alone in patients with newly diagnosed DLBCL in the EPCORE DLBCL-2 Phase 3 study
Importance:8/10
Sentiment:
0.85
Phase 3DLBCLbispecific antibodycombination therapypositive dataoncology
Read the original article
Published by PR Newswire Biotech on October 5, 2026 6:54 PM